Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

In a phase 2 study, enoblituzumab - a humanized Fc-engineered B7-H3–targeting antibody - was safe and showed preliminary evidence of potential clinical activity in men with high-risk ProstateCancer DocEShenderov HopkinsMedicine

) Total unique T-cell clonotypes expanded in tumor or peripheral blood at prostatectomy versus fraction of peripheral clones expanded and detected intratumorally. Each point on the scatter plots represents a patient. Blue dots indicate responders for a given outcome and red dots indicate non-responders.

Genes that remained significant after Benjamini and Yekutieli False Discovery Rate are in blue and labeled. Matched 1:1 untreated controls by grade group, stage, margins, block age [within 2 years], age [within 2 years], and self-reported race. Tumor regions isolated by macrodissection. Extended Data Fig. 6 Grouped boxplots of difference in mean log2 marker level of upregulated proteins by clinical outcome using DSP of the TME in pretreatment biopsies and post-treatment prostatectomies following B7-H3 monoclonal antibody treatment., protein marker status by PSA response at 12 months after prostatectomy versus PSA recurrence. Protein expression was assessed in n = 27 tissue samples from n = 32 patients .

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Use of mobile diagnostics and digital clinical trials in cardiology - Nature MedicineUse of mobile diagnostics and digital clinical trials in cardiology. Comment from Sinje Gehr, Nandha Kumar Balasubramaniam & Christoph Russmann, Health Campus Goettingen, harvardmed. Published as part of our series - Rethinking Evidence in Medicine. harvardmed Outstanding diagnostics discoveries
Source: NatureMedicine - 🏆 451. / 53 Read more »

'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drugThe antidiabetic drug Ozempic has been called 'the worst-kept secret in Hollywood.' It causes rapid weight loss — and celebs have scrambled to get their hands on it for off-label, aesthetic purposes. But its popularity has a price. Phentermine is cheaper Weight loss… I like a little meat on the bones
Source: NPR - 🏆 96. / 63 Read more »

AI chatbots like ChatGPT could soon play a significant role in medicineAdvanced LLM chatbots such as ChatGPT have been found to provide surprisingly accurate medical information.
Source: IntEngineering - 🏆 287. / 63 Read more »

'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drugThe Novo Nordisk diabetes medication was found to cause significant weight loss in users and has since become a blockbuster drug and very big business.
Source: WBUR - 🏆 274. / 63 Read more »

An atlas of genetic scores to predict multi-omic traits - NatureA machine learning approach is used to analyse multi-omics (proteomics, metabolomics and transcriptomics) data, producing genetic scores for more than 17,000 biomolecular traits in human blood, and identifying possible associations with disease. Read the abstract dumbed down: Scientists are using a lot of technology to figure out the relationship between diseases and genetics. They looked at a group of 50,000 people who had different kinds of data like blood proteins and chemicals and they used a machine to put it all…
Source: Nature - 🏆 64. / 68 Read more »